ArticleFrontiers in immunology2026
Genomic and immunological differences in endometrial cancer: a comparative study between young and old Asian patients.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial carcinoma (EC) demonstrates a pronounced age-related disparity in clinical outcomes, yet the underlying genomic and molecular mechanisms remain incompletely characterized, especially across Asian populations. Methods: We performed an integrated genomic analysis of two independent cohorts: the MSK-MET Asian cohort (n=94) and a Chinese EC cohort, EC-3rd-SYSU (n=18). Patients were stratified by age (young, ≤50 years; old, >50 years). We compared mutation spectra, pathway enrichment, tumor mutation burden (TMB), microsatellite instability (MSI), and survival outcomes between age groups. Results: Across both cohorts, PTEN, PIK3CA, and ARID1A were the most frequently mutated genes, forming a conserved oncogenic core centered on PI3K/AKT signaling and chromatin remodeling. Younger patients showed enrichment of CTNNB1 and PTEN mutations, while older patients exhibited higher frequencies of TP53, ARID1A, and MSH6 alterations. Younger tumors were characterized by activation of stemness and metabolic signaling pathways, whereas older tumors were enriched in cellular senescence, endocrine resistance, and longevity regulation pathways. No significant age-associated differences were observed in TMB or MSI status. The Chinese cohort had higher mutation rates of PTEN, KRAS, and FGFR2, while TP53 and PIK3R1 mutations were more frequent in the MSK-MET cohort. These age-specific molecular subtypes correlated with significant survival differences. Conclusions: Our study identifies conserved age-specific molecular subtypes of EC and reveals population-specific genomic features, underscoring the need for age-tailored and ethnicity-aware therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.